K
Kai Lin
Researcher at University of California, San Diego
Publications - 81
Citations - 3741
Kai Lin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Hepatitis C virus & Replicon. The author has an hindex of 25, co-authored 67 publications receiving 3522 citations. Previous affiliations of Kai Lin include China West Normal University & Novartis.
Papers
More filters
Journal ArticleDOI
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
Robert B. Perni,Susan J. Almquist,Randal Byrn,Gurudatt Chandorkar,Pravin Chaturvedi,Lawrence F. Courtney,Caroline Decker,Kirk Dinehart,Cynthia A. Gates,Scott L. Harbeson,Angela D. Heiser,Gururaj Kalkeri,Elaine Kolaczkowski,Kai Lin,Yu-Ping Luong,B. Govinda Rao,William P. Taylor,John A. Thomson,Roger D. Tung,Yunyi Wei,Ann D. Kwong,Chao Lin +21 more
TL;DR: The overall preclinical profile of VX-950 supports its candidacy as a novel oral therapy against hepatitis C and a recently developed HCV protease mouse model showed excellent inhibition of HCV NS3-4A protease activity in the liver.
Journal ArticleDOI
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 STRUCTURAL ANALYSIS INDICATES DIFFERENT RESISTANCE MECHANISMS
Chao Lin,Kai Lin,Yu-Ping Luong,B. Govinda Rao,Yunyi Wei,Debra L. Brennan,John R. Fulghum,Hsun-Mei Hsiao,Sue Ma,John Maxwell,Kevin M. Cottrell,Robert B. Perni,Cynthia A. Gates,Ann D. Kwong +13 more
TL;DR: In vitro resistance studies using a subgenomic replicon system to compare VX-950 with another HCV NS3·4A protease inhibitor, BILN 2061, are described and modeling analysis suggests that there are different mechanisms of resistance to V X-950 and BILn 2061.
Journal ArticleDOI
An adenosine nucleoside inhibitor of dengue virus
Zheng Yin,Zheng Yin,Yen Liang Chen,Wouter Schul,Qing Yin Wang,Feng Gu,Jeyaraj Duraiswamy,Ravinder Reddy Kondreddi,Pornwaratt Niyomrattanakit,Suresh B. Lakshminarayana,Anne Goh,Hao Ying Xu,Wei Liu,Boping Liu,Joanne Y.H. Lim,Chuan Young Ng,Min Qing,Chin Chin Lim,Andy Yip,Gang Wang,Wai Ling Chan,Hui Pen Tan,Kai Lin,Bo Zhang,Gang Zou,Kristen A. Bernard,Christine E. Garrett,Karen Beltz,Min Dong,Margaret Weaver,Handan He,Arkadius Pichota,Véronique Dartois,Thomas H. Keller,Pei Yong Shi +34 more
TL;DR: The results have proved the concept that a nucleoside inhibitor could be developed for potential treatment of flavivirus infections and suppressed peak viremia, reduced cytokine elevation, and completely prevented the infected mice from death.
Journal ArticleDOI
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
Chao Lin,Cynthia A. Gates,B. Govinda Rao,Debra L. Brennan,John R. Fulghum,Yu-Ping Luong,J. Daniel Frantz,Kai Lin,Sue Ma,Yunyi Wei,Robert B. Perni,Ann D. Kwong +11 more
TL;DR: This study identified mutants that are cross-resistant to both HCV protease inhibitors that displayed significantly diminished fitness (or replication capacity) in a transient replicon cell system.
Journal ArticleDOI
VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells
TL;DR: The combination of VX-950 and alpha interferon was additive to moderately synergistic in reducing HCV RNA in replicon cells with no significant increase in cytotoxicity and the benefit of the combination was sustained over time.